Evaluation of drug-eluting stents' coating durability - Clinical and regulatory implications

Journal of Biomedical Materials Research - Part B Applied Biomaterials

Volumn 91, Issue 1, 2009, Pages 441-451

  Levy, Yair ^a,b   Mandler, Daniel ^c   Weinberger, Judah ^d   Domb, Abraham J ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b Elutex Ltd   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Coating; Drug eluting stents; Safety; Testing

Indexed keywords

COATED STENTS; COATING DEFECTS; COATING MODEL; COATING PROPERTIES; DELETERIOUS EFFECTS; DRUG RELEASE; DRUG-ELUTING STENTS; DURABILITY TEST; FOOD AND DRUG ADMINISTRATION; IN-VITRO; LIGHT MICROSCOPY; SAFETY; SAFETY ISSUES; SPRAY COATING; STENT COATINGS; SURFACE ADHESION; TESTING METHODOLOGY;

ARTIFICIAL ORGANS; BIODEGRADABLE POLYMERS; CHROMATOGRAPHIC ANALYSIS; DEFECTS; DURABILITY; HIGH PRESSURE LIQUID CHROMATOGRAPHY; SAFETY TESTING; SCANNING ELECTRON MICROSCOPY; SEMICONDUCTOR QUANTUM DOTS; STAINLESS STEEL;

PLASTIC COATINGS;

PACLITAXEL; POLYMER;

ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ELUTING STENT; DRUG RELEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN-STENT RESTENOSIS; MATERIAL COATING; SCANNING ELECTRON MICROSCOPY;

ANGIOPLASTY, BALLOON, CORONARY; COATED MATERIALS, BIOCOMPATIBLE; DEVICE APPROVAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG-ELUTING STENTS; HUMANS; MATERIALS TESTING; MICROSCOPY, ELECTRON, SCANNING; SURFACE PROPERTIES;

EID: 70049092349     PISSN: 15524973     EISSN: 15524981     Source Type: Journal    
DOI: 10.1002/jbm.b.31420     Document Type: Article

References (24)

1. Saia F, Marzocchi A, Serruys PW. Drug-eluting stents: The third revolution in percutaneous coronary intervention. Ital Heart J 2005;6:289-303.
2. Ryan AJ, Cohen DJ. Are drug-eluting stents cost-effective? It depends on whom you ask. Circulation 2006;114:1736-1744.
3. Belle EV, Susen S, Jude B, Bertrand ME. Drug eluting stents: Trading restenosis for thrombosis. J Thromb Haemost 2007;5:238-245. (Pubitemid 46958839)
4. Kim HL, Park KW, Kwak JJ, Kim YS, Sir JJ, Lee SJ, Lee HY, Chang HJ, Kang HJ, Cho YS, Chung WY, Chae HH, Choi DJ, Kim HS, Oh BH, Park YB, Koo BK. Stent-related cardiac events after non-cardiac surgery: Drug-eluting stent vs. bare metal stent. Int J Cardiol 2008;123:353-354.
5. Sharifkazemi MB, Zamirian M, Aslani A. A current problem in cardiology: Very late thrombosis after implantation of sirolimus-eluting stents. Cardiology 2007;108:273-274. (Pubitemid 350126470)
6. Ruchin PE, Muller DW, Faddy SC, Baron DW, Roy PR, Wilson SH. Long-term clinical follow-up of sirolimus-eluting (cyphertm) coronary stents in the treatment of instent restenosis in an unselected population. Heart Lung Circ 2007;16:440-446. (Pubitemid 350091402)
7. Unger F. Drug-eluting stents a nightmare? Interact Cardiovasc Thorac Surg 2007;6:813-814.
8. Otsuka Y, Chronos NAF, Apkarian RP, Robinson KA. Scanning electron microscopic analysis of defects in polymer coatings of three commercially available stents: Comparison of BiodivYsio, Taxus and Cypher Stents. J Invasive Cardiol 2007;19:71-76.
9. Windecker S, Mierer B. Late coronary late thrombosis. Circulation 2007;116:1952-1965.
10. Slottow T, Waksman R. Drug-eluting stent safety. Am J Cardiol 2007;100(8B):10M-17M.
11. Sims J. Update on drug-eluting stents. Dimens Crit Care Nurs 2007;26:237-240.
12. Nakazawa G, Finn AV, Virmani R. Drug-eluting stent pathology - Should we still be cautious? Nat Clin Pract Cardiovasc Med 2008;5:1.
13. Austin D, Pell JP, Oldroyd KG. Drug-eluting stents: Do the risks really overweigh the benefits? Heart 2008;94:127-128.
14. Melikian N, Wijns W. Drug-eluting stents - A critique. Heart 2008;94:145-152.
15. USFDA. ( 2003). Summary of safety and effectiveness data. Cypher™ Sirolimus-eluting Coronary Stent on RAPTOR® Over-the-Wire Delivery System or RAPTORRAIL® Rapid Exchange Delivery System - P020026. Available at http://www.fda.gov/cdrh/pdf2/p020026.html.
16. USFDA. (2005). Guidance for industry and FDA staff: Nonclinical tests and recommended labeling for intravascular stents and associated delivery systems. Available at http://www.fda.gov/cdrh/ode/guidance/1545.html.
17. Boam AB. Regulatory issues facing the development of drug-eluting stents: A US FDA perspective. Expert Rev Med Devices 2006;3:297-300.
18. Laskey WK. Cardiovascular device development: Drug-eluting stents and implantable devices for the treatment of heart failure - The view from the Circulatory System Advisory Panel. Am J Ther 2005;12:179-182.
19. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, Van GA, Steg PG, Morel MA, Mauri L, Vranckx P, Mcfadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007;115:2344-2351. (Pubitemid 46685903)
20. USFDA. ( 2008). Summary of safety and effectiveness data. TAXUS™ Express 2™ Paclitaxel-Eluting Coronary Stent System (Monorail and Over-the-Wire) - P030025. Available at http://www.fda.gov/cdrh/pdf3/P030025b.pdf http.
21. USFDA. ( 2008). Summary of safety and effectiveness data. Endeavor™ Zotarolimus-Eluting Coronary Stent on the Over-the-Wire (OTW), Rapid Exchange (RX), or Multi Exchange II (MX2) Stent Delivery Systems - P060033. Available at http://www.fda.gov/cdrh/pdf6/p060033.html.
22. Van der Giessen WJ, Lincoff AM, Schwartz RS, van Beusekom HM, Serruys PW, Holmes DR, Ellis SG, Topol EJ. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996;94:1690-1697.
23. De Scheerder IK, Wilczek KL, Verbeken EV, Vandorpe J, Lan PN, Schacht E, De Geest H, Piessens J. Biocompatibility of polymer-coated oversized metallic stents implanted in normal porcine coronary arteries. Atherosclerosis 1995;114:105-114.
24. Levy Y, Mandler D, Weinberger J, Domb AJ. Drug-eluting stent platform with improved durability and controllability properties, obtained via electrografted adhesive promotion layer. Forthcoming.